Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo

Phase 1Active Not RecruitingNCT07044141

Lahore General Hospital20 enrolled

Overview

20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib

Total 20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine 50mg twice daily. 10 will be given tofacitinib 5mg twice daily. For 6 months

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Vitiligo

Interventions

AzathioprineDRUG

azathioprine 50mg twice daily will be given

TofacitinibDRUG

It is a janus kinase inhibitor

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient of vitiligo with any VASI both genders 18 to 60yrs Exclusion Criteria: * pregnancy/lactation Hyerlipidrmia Patient on immunemodulator Histry pf tuberculosis Immunocompromised patients

Locations (1)

Lahore general.hospital

Lahore, Punjab Province, Pakistan

Outcomes

Primary Outcomes

VASI improvement upto 50%

Study will be considered efficacious if 50% improvement in VASI from baseline is seen by end of 6 months of study

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.